Cargando…
Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755666/ https://www.ncbi.nlm.nih.gov/pubmed/36530969 http://dx.doi.org/10.3389/fonc.2022.949400 |
_version_ | 1784851466182197248 |
---|---|
author | Zhuang, Tony Zibo Harik, Lara Force, Seth Hadadi, Agreen Bilen, Mehmet Asim Brown, Jacqueline T. Carthon, Bradley C. Goldman, Jamie Kucuk, Omer Master, Viraj A. Nazha, Bassel |
author_facet | Zhuang, Tony Zibo Harik, Lara Force, Seth Hadadi, Agreen Bilen, Mehmet Asim Brown, Jacqueline T. Carthon, Bradley C. Goldman, Jamie Kucuk, Omer Master, Viraj A. Nazha, Bassel |
author_sort | Zhuang, Tony Zibo |
collection | PubMed |
description | The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radical nephrectomy and metastasectomy of known pulmonary disease site, both without a clinical need for perioperative blood transfusions. The patient continues to be without evidence of disease and without additional need for systemic therapy over a year after his radical nephrectomy. The case highlights that cytoreductive nephrectomy continues to play a role in the era of immune checkpoint inhibitors. |
format | Online Article Text |
id | pubmed-9755666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97556662022-12-17 Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report Zhuang, Tony Zibo Harik, Lara Force, Seth Hadadi, Agreen Bilen, Mehmet Asim Brown, Jacqueline T. Carthon, Bradley C. Goldman, Jamie Kucuk, Omer Master, Viraj A. Nazha, Bassel Front Oncol Oncology The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radical nephrectomy and metastasectomy of known pulmonary disease site, both without a clinical need for perioperative blood transfusions. The patient continues to be without evidence of disease and without additional need for systemic therapy over a year after his radical nephrectomy. The case highlights that cytoreductive nephrectomy continues to play a role in the era of immune checkpoint inhibitors. Frontiers Media S.A. 2022-12-02 /pmc/articles/PMC9755666/ /pubmed/36530969 http://dx.doi.org/10.3389/fonc.2022.949400 Text en Copyright © 2022 Zhuang, Harik, Force, Hadadi, Bilen, Brown, Carthon, Goldman, Kucuk, Master and Nazha https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhuang, Tony Zibo Harik, Lara Force, Seth Hadadi, Agreen Bilen, Mehmet Asim Brown, Jacqueline T. Carthon, Bradley C. Goldman, Jamie Kucuk, Omer Master, Viraj A. Nazha, Bassel Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report |
title | Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report |
title_full | Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report |
title_fullStr | Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report |
title_full_unstemmed | Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report |
title_short | Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report |
title_sort | durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a jehovah’s witness: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755666/ https://www.ncbi.nlm.nih.gov/pubmed/36530969 http://dx.doi.org/10.3389/fonc.2022.949400 |
work_keys_str_mv | AT zhuangtonyzibo durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport AT hariklara durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport AT forceseth durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport AT hadadiagreen durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport AT bilenmehmetasim durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport AT brownjacquelinet durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport AT carthonbradleyc durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport AT goldmanjamie durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport AT kucukomer durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport AT masterviraja durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport AT nazhabassel durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport |